Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 18;12(1):97. doi: 10.1038/s41419-020-03340-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — A Cell proliferation was detected by CCK-8 after different concentrations (0, 1.25, 2.5, 5, or 10 µg/ml) and different durations (12 h or 24 h) of epirubicin treatment in two breast cancer cell lines. B mRNA level of MEDAG in breast cancer cells treated with different concentration of epirubicin (0, 2.5, 5, or 10 µg/ml) was detected by qRT-PCR. C Western blot analysis showing the protein expression of MEDAG in breast cancer treated as described above. Right: quantitative analysis of the optical density ratio of MEDAG compared with β-actin is shown. D Cell viability was assessed by CCK-8 after MEDAG knockdown and treatment with epirubicin (5 µg/ml,12 h). E The expression of PARP was detected by western blot analysis of cells treated as described above. Right: quantitative analysis of the optical density ratio of c-PARP compared with β-actin is shown. F Cell viability was assessed by CCK-8 after MEDAG overexpression and treatment with epirubicin. G The expression of PARP was detected by western blot analysis of cells treated as described above. Right: quantitative analysis of the optical density ratio of c-PARP compared with β-actin is shown. The values represent mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs the corresponding group.